#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=The well-characterized GWI symptoms are GI inflammatory disease , chronic fatigue , neuroinflammation , and cognitive impairment .
2-1	14-17	The	abstract[3]	new[3]	coref	2-6[5_3]
2-2	18-36	well-characterized	abstract[3]	new[3]	_	_
2-3	37-40	GWI	abstract|abstract[3]	new|new[3]	coref	4-20
2-4	41-49	symptoms	abstract[3]	new[3]	_	_
2-5	50-53	are	_	_	_	_
2-6	54-56	GI	place|abstract[5]	new|giv[5]	coref|coref|coref|coref	3-13|6-4[39_5]|3-13|6-4[39_5]
2-7	57-69	inflammatory	abstract[5]	giv[5]	_	_
2-8	70-77	disease	abstract[5]	giv[5]	_	_
2-9	78-79	,	abstract[5]	giv[5]	_	_
2-10	80-87	chronic	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-11	88-95	fatigue	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-12	96-97	,	abstract[5]	giv[5]	_	_
2-13	98-115	neuroinflammation	abstract[5]|abstract	giv[5]|new	coref	3-15
2-14	116-117	,	abstract[5]	giv[5]	_	_
2-15	118-121	and	abstract[5]	giv[5]	_	_
2-16	122-131	cognitive	abstract[5]|abstract[8]	giv[5]|new[8]	_	_
2-17	132-142	impairment	abstract[5]|abstract[8]	giv[5]|new[8]	_	_
2-18	143-144	.	_	_	_	_

#Text=The current study investigates a mechanistic analysis of the gut virome-bacteriome mediated GI and neuroinflammation .
3-1	145-148	The	abstract[9]	new[9]	_	_
3-2	149-156	current	abstract[9]	new[9]	_	_
3-3	157-162	study	abstract[9]	new[9]	_	_
3-4	163-175	investigates	_	_	_	_
3-5	176-177	a	abstract[10]	new[10]	coref	8-20[60_10]
3-6	178-189	mechanistic	abstract[10]	new[10]	_	_
3-7	190-198	analysis	abstract[10]	new[10]	_	_
3-8	199-201	of	abstract[10]	new[10]	_	_
3-9	202-205	the	abstract[10]|abstract[12]	new[10]|new[12]	_	_
3-10	206-209	gut	abstract[10]|abstract|abstract[12]	new[10]|new|new[12]	coref	6-5
3-11	210-227	virome-bacteriome	abstract[10]|abstract[12]	new[10]|new[12]	_	_
3-12	228-236	mediated	_	_	_	_
3-13	237-239	GI	abstract	giv	coref	8-14
3-14	240-243	and	_	_	_	_
3-15	244-261	neuroinflammation	abstract	giv	ana	4-5
3-16	262-263	.	_	_	_	_

#Text=To our knowledge , this is the first study that examined GW chemical-induced virome dysbiosis and bacteriome-virome interactions in GWI .
4-1	264-266	To	_	_	_	_
4-2	267-270	our	person|abstract[16]	acc|new[16]	ana|ana	5-2|5-2
4-3	271-280	knowledge	abstract[16]	new[16]	_	_
4-4	281-282	,	_	_	_	_
4-5	283-287	this	abstract	giv	coref	4-7[18_0]
4-6	288-290	is	_	_	_	_
4-7	291-294	the	abstract[18]	giv[18]	coref	5-2[26_18]
4-8	295-300	first	abstract[18]	giv[18]	_	_
4-9	301-306	study	abstract[18]	giv[18]	_	_
4-10	307-311	that	_	_	_	_
4-11	312-320	examined	_	_	_	_
4-12	321-323	GW	abstract|abstract[21]|abstract[22]	new|new[21]|new[22]	coref|coref|coref|coref|coref|coref|coref|coref|coref	5-10|5-14[31_21]|7-18[49_22]|5-10|5-14[31_21]|7-18[49_22]|5-10|5-14[31_21]|7-18[49_22]
4-13	324-340	chemical-induced	abstract[21]|abstract[22]	new[21]|new[22]	_	_
4-14	341-347	virome	abstract|abstract[21]|abstract[22]	new|new[21]|new[22]	coref	7-11[45_0]
4-15	348-357	dysbiosis	abstract[21]|abstract[22]	new[21]|new[22]	_	_
4-16	358-361	and	abstract[22]	new[22]	_	_
4-17	362-379	bacteriome-virome	abstract[22]|abstract[23]	new[22]|new[23]	_	_
4-18	380-392	interactions	abstract[22]|abstract[23]	new[22]|new[23]	_	_
4-19	393-395	in	abstract[22]|abstract[23]	new[22]|new[23]	_	_
4-20	396-399	GWI	abstract[22]|abstract[23]|place	new[22]|new[23]|giv	coref	6-11
4-21	400-401	.	_	_	_	_

#Text=In our previous study , we have shown that GW chemical exposure causes bacterial dysbiosis and that led to the loss of healthy gut bacteria such as Lactobacillus and Bifidobacterium .
5-1	402-404	In	_	_	_	_
5-2	405-408	our	person|abstract[26]	giv|giv[26]	ana|coref|ana|coref	5-6|8-1[52_26]|5-6|8-1[52_26]
5-3	409-417	previous	abstract[26]	giv[26]	_	_
5-4	418-423	study	abstract[26]	giv[26]	_	_
5-5	424-425	,	_	_	_	_
5-6	426-428	we	person	giv	ana	9-5
5-7	429-433	have	_	_	_	_
5-8	434-439	shown	_	_	_	_
5-9	440-444	that	_	_	_	_
5-10	445-447	GW	abstract|abstract[29]	giv|new[29]	coref|coref|coref|coref	10-10|10-9[75_29]|10-10|10-9[75_29]
5-11	448-456	chemical	abstract[29]	new[29]	_	_
5-12	457-465	exposure	abstract[29]	new[29]	_	_
5-13	466-472	causes	_	_	_	_
5-14	473-482	bacterial	substance|abstract[31]	new|giv[31]	coref|coref|coref|coref	6-1[37_31]|7-18|6-1[37_31]|7-18
5-15	483-492	dysbiosis	abstract[31]	giv[31]	_	_
5-16	493-496	and	_	_	_	_
5-17	497-501	that	_	_	_	_
5-18	502-505	led	_	_	_	_
5-19	506-508	to	_	_	_	_
5-20	509-512	the	event[32]	new[32]	_	_
5-21	513-517	loss	event[32]	new[32]	_	_
5-22	518-520	of	event[32]	new[32]	_	_
5-23	521-528	healthy	event[32]|animal[33]	new[32]|new[33]	_	_
5-24	529-532	gut	event[32]|animal[33]	new[32]|new[33]	_	_
5-25	533-541	bacteria	event[32]|animal[33]	new[32]|new[33]	_	_
5-26	542-546	such	event[32]|animal[33]	new[32]|new[33]	_	_
5-27	547-549	as	event[32]|animal[33]	new[32]|new[33]	_	_
5-28	550-563	Lactobacillus	event[32]|animal[33]|substance	new[32]|new[33]|new	_	_
5-29	564-567	and	event[32]|animal[33]	new[32]|new[33]	_	_
5-30	568-583	Bifidobacterium	event[32]|animal[33]|substance	new[32]|new[33]|new	_	_
5-31	584-585	.	_	_	_	_

#Text=Gut dysbiosis induced leaky gut symptoms and systemic inflammation in GWI .
6-1	586-589	Gut	person|abstract[37]	new|giv[37]	coref|coref|coref|coref	7-18[48_37]|20-1|7-18[48_37]|20-1
6-2	590-599	dysbiosis	abstract[37]	giv[37]	_	_
6-3	600-607	induced	_	_	_	_
6-4	608-613	leaky	abstract[39]	giv[39]	coref	19-34[0_39]
6-5	614-617	gut	abstract|abstract[39]	giv|giv[39]	coref	7-11
6-6	618-626	symptoms	abstract[39]	giv[39]	_	_
6-7	627-630	and	abstract[39]	giv[39]	_	_
6-8	631-639	systemic	abstract[39]|abstract[40]	giv[39]|new[40]	ana	7-6[0_40]
6-9	640-652	inflammation	abstract[39]|abstract[40]	giv[39]|new[40]	_	_
6-10	653-655	in	abstract[39]|abstract[40]	giv[39]|new[40]	_	_
6-11	656-659	GWI	abstract[39]|abstract[40]|place	giv[39]|new[40]|giv	coref	9-14
6-12	660-661	.	_	_	_	_

#Text=In a recent review , it has been reported that gut virome is the missing link between bacterial dysbiosis and host immunity .
7-1	662-664	In	_	_	_	_
7-2	665-666	a	abstract[42]	new[42]	_	_
7-3	667-673	recent	abstract[42]	new[42]	_	_
7-4	674-680	review	abstract[42]	new[42]	_	_
7-5	681-682	,	_	_	_	_
7-6	683-685	it	abstract	giv	coref	15-32[138_0]
7-7	686-689	has	_	_	_	_
7-8	690-694	been	_	_	_	_
7-9	695-703	reported	_	_	_	_
7-10	704-708	that	_	_	_	_
7-11	709-712	gut	abstract|abstract[45]	giv|giv[45]	coref|coref|coref|coref	7-14[46_45]|11-28|7-14[46_45]|11-28
7-12	713-719	virome	abstract[45]	giv[45]	_	_
7-13	720-722	is	_	_	_	_
7-14	723-726	the	abstract[46]	giv[46]	coref	8-9[54_46]
7-15	727-734	missing	abstract[46]	giv[46]	_	_
7-16	735-739	link	abstract[46]	giv[46]	_	_
7-17	740-747	between	abstract[46]	giv[46]	_	_
7-18	748-757	bacterial	abstract[46]|substance|abstract[48]|abstract[49]	giv[46]|giv|giv[48]|giv[49]	coref|coref|coref|coref|coref|coref	14-14[122_0]|15-14[131_48]|14-14[122_0]|15-14[131_48]|14-14[122_0]|15-14[131_48]
7-19	758-767	dysbiosis	abstract[46]|abstract[48]|abstract[49]	giv[46]|giv[48]|giv[49]	_	_
7-20	768-771	and	abstract[46]|abstract[49]	giv[46]|giv[49]	_	_
7-21	772-776	host	abstract[46]|abstract[49]|person|abstract[51]	giv[46]|giv[49]|new|new[51]	coref|coref	11-21[95_0]|11-21[95_0]
7-22	777-785	immunity	abstract[46]|abstract[49]|abstract[51]	giv[46]|giv[49]|new[51]	_	_
7-23	786-787	.	_	_	_	_

#Text=The same study also described the role of virome in TLR signaling and GI diseases and hence concluding that virome analysis may lead to a novel therapeutic strategy for GI complications .
8-1	788-791	The	abstract[52]	giv[52]	coref	9-1[64_52]
8-2	792-796	same	abstract[52]	giv[52]	_	_
8-3	797-802	study	abstract[52]	giv[52]	_	_
8-4	803-807	also	_	_	_	_
8-5	808-817	described	_	_	_	_
8-6	818-821	the	abstract[53]	new[53]	_	_
8-7	822-826	role	abstract[53]	new[53]	_	_
8-8	827-829	of	abstract[53]	new[53]	_	_
8-9	830-836	virome	abstract[53]|abstract[54]	new[53]|giv[54]	coref	8-20[0_54]
8-10	837-839	in	abstract[53]|abstract[54]	new[53]|giv[54]	_	_
8-11	840-843	TLR	abstract[53]|abstract[54]|abstract|abstract[56]	new[53]|giv[54]|new|new[56]	_	_
8-12	844-853	signaling	abstract[53]|abstract[54]|abstract[56]	new[53]|giv[54]|new[56]	_	_
8-13	854-857	and	abstract[53]|abstract[54]	new[53]|giv[54]	_	_
8-14	858-860	GI	abstract[53]|abstract[54]|object|abstract[58]	new[53]|giv[54]|giv|new[58]	coref|coref	8-30|8-30
8-15	861-869	diseases	abstract[53]|abstract[54]|abstract[58]	new[53]|giv[54]|new[58]	_	_
8-16	870-873	and	_	_	_	_
8-17	874-879	hence	_	_	_	_
8-18	880-890	concluding	_	_	_	_
8-19	891-895	that	_	_	_	_
8-20	896-902	virome	abstract|abstract[60]	giv|giv[60]	coref|coref	11-28[98_0]|11-28[98_0]
8-21	903-911	analysis	abstract[60]	giv[60]	_	_
8-22	912-915	may	_	_	_	_
8-23	916-920	lead	_	_	_	_
8-24	921-923	to	_	_	_	_
8-25	924-925	a	abstract[61]	new[61]	_	_
8-26	926-931	novel	abstract[61]	new[61]	_	_
8-27	932-943	therapeutic	abstract[61]	new[61]	_	_
8-28	944-952	strategy	abstract[61]	new[61]	_	_
8-29	953-956	for	abstract[61]	new[61]	_	_
8-30	957-959	GI	abstract[61]|abstract|abstract[63]	new[61]|giv|new[63]	coref|coref|coref|coref	15-19|17-11[159_63]|15-19|17-11[159_63]
8-31	960-973	complications	abstract[61]|abstract[63]	new[61]|new[63]	_	_
8-32	974-975	.	_	_	_	_

#Text=The above study prompted us to explore the role of enteric viruses in GWI pathology and as a probable therapeutic target .
9-1	976-979	The	abstract[64]	giv[64]	coref	10-2[72_64]
9-2	980-985	above	abstract[64]	giv[64]	_	_
9-3	986-991	study	abstract[64]	giv[64]	_	_
9-4	992-1000	prompted	_	_	_	_
9-5	1001-1003	us	person	giv	ana	10-6
9-6	1004-1006	to	_	_	_	_
9-7	1007-1014	explore	_	_	_	_
9-8	1015-1018	the	abstract[66]	new[66]	_	_
9-9	1019-1023	role	abstract[66]	new[66]	_	_
9-10	1024-1026	of	abstract[66]	new[66]	_	_
9-11	1027-1034	enteric	abstract[66]|object|object[68]	new[66]|new|new[68]	coref|coref|coref|coref	11-18[94_68]|13-11|11-18[94_68]|13-11
9-12	1035-1042	viruses	abstract[66]|object[68]	new[66]|new[68]	_	_
9-13	1043-1045	in	abstract[66]|object[68]	new[66]|new[68]	_	_
9-14	1046-1049	GWI	abstract[66]|object[68]|abstract|abstract[70]	new[66]|new[68]|giv|new[70]	coref|coref|coref|coref	11-31|19-32[176_70]|11-31|19-32[176_70]
9-15	1050-1059	pathology	abstract[66]|object[68]|abstract[70]	new[66]|new[68]|new[70]	_	_
9-16	1060-1063	and	abstract[66]	new[66]	_	_
9-17	1064-1066	as	abstract[66]	new[66]	_	_
9-18	1067-1068	a	abstract[66]|abstract[71]	new[66]|new[71]	_	_
9-19	1069-1077	probable	abstract[66]|abstract[71]	new[66]|new[71]	_	_
9-20	1078-1089	therapeutic	abstract[66]|abstract[71]	new[66]|new[71]	_	_
9-21	1090-1096	target	abstract[66]|abstract[71]	new[66]|new[71]	_	_
9-22	1097-1098	.	_	_	_	_

#Text=In the present study , we found that the GW chemical exposure led to an increase in virome richness and relative abundance of dsDNA bacteriophages Myoviridae , Siphoviridae , and Caudovirales and decreased relative abundance of ssDNA bacteriophages Microviridae .
10-1	1099-1101	In	_	_	_	_
10-2	1102-1105	the	abstract[72]	giv[72]	coref	15-51[0_72]
10-3	1106-1113	present	abstract[72]	giv[72]	_	_
10-4	1114-1119	study	abstract[72]	giv[72]	_	_
10-5	1120-1121	,	_	_	_	_
10-6	1122-1124	we	person	giv	ana	11-1
10-7	1125-1130	found	_	_	_	_
10-8	1131-1135	that	_	_	_	_
10-9	1136-1139	the	abstract[75]	giv[75]	_	_
10-10	1140-1142	GW	abstract|abstract[75]	giv|giv[75]	coref	24-10
10-11	1143-1151	chemical	abstract[75]	giv[75]	_	_
10-12	1152-1160	exposure	abstract[75]	giv[75]	_	_
10-13	1161-1164	led	_	_	_	_
10-14	1165-1167	to	_	_	_	_
10-15	1168-1170	an	abstract[76]	new[76]	_	_
10-16	1171-1179	increase	abstract[76]	new[76]	_	_
10-17	1180-1182	in	abstract[76]	new[76]	_	_
10-18	1183-1189	virome	abstract[76]|abstract[77]|abstract[78]	new[76]|new[77]|new[78]	coref|coref|coref|coref	24-9[212_77]|24-9[213_78]|24-9[212_77]|24-9[213_78]
10-19	1190-1198	richness	abstract[76]|abstract[77]|abstract[78]	new[76]|new[77]|new[78]	_	_
10-20	1199-1202	and	abstract[76]|abstract[78]	new[76]|new[78]	_	_
10-21	1203-1211	relative	abstract[76]|abstract[78]|abstract[79]	new[76]|new[78]|new[79]	_	_
10-22	1212-1221	abundance	abstract[76]|abstract[78]|abstract[79]	new[76]|new[78]|new[79]	_	_
10-23	1222-1224	of	abstract[76]|abstract[78]|abstract[79]	new[76]|new[78]|new[79]	_	_
10-24	1225-1230	dsDNA	abstract[76]|abstract[78]|abstract[79]|substance|object[82]	new[76]|new[78]|new[79]|new|new[82]	_	_
10-25	1231-1245	bacteriophages	abstract[76]|abstract[78]|abstract[79]|place|object[82]	new[76]|new[78]|new[79]|new|new[82]	coref	10-38
10-26	1246-1256	Myoviridae	abstract[76]|abstract[78]|abstract[79]|object[82]	new[76]|new[78]|new[79]|new[82]	_	_
10-27	1257-1258	,	abstract[76]|abstract[78]|abstract[79]	new[76]|new[78]|new[79]	_	_
10-28	1259-1271	Siphoviridae	abstract[76]|abstract[78]|abstract[79]|substance	new[76]|new[78]|new[79]|new	_	_
10-29	1272-1273	,	abstract[76]|abstract[78]|abstract[79]	new[76]|new[78]|new[79]	_	_
10-30	1274-1277	and	abstract[76]|abstract[78]|abstract[79]	new[76]|new[78]|new[79]	_	_
10-31	1278-1290	Caudovirales	abstract[76]|abstract[78]|abstract[79]|animal	new[76]|new[78]|new[79]|new	_	_
10-32	1291-1294	and	_	_	_	_
10-33	1295-1304	decreased	_	_	_	_
10-34	1305-1313	relative	abstract[85]	new[85]	_	_
10-35	1314-1323	abundance	abstract[85]	new[85]	_	_
10-36	1324-1326	of	abstract[85]	new[85]	_	_
10-37	1327-1332	ssDNA	abstract[85]|substance|object[88]	new[85]|new|new[88]	_	_
10-38	1333-1347	bacteriophages	abstract[85]|place|object[88]	new[85]|giv|new[88]	_	_
10-39	1348-1360	Microviridae	abstract[85]|object[88]	new[85]|new[88]	_	_
10-40	1361-1362	.	_	_	_	_

#Text=We used a broad-spectrum antiviral compound Ribavirin to test the hypothesis that ( a ) inhibition of gut viruses in the host may prove the role of gut virome in GWI and ( b ) antiviral treatment may help to reconstruct and restore the virome signature in GWI .
11-1	1363-1365	We	person	giv	ana	13-1
11-2	1366-1370	used	_	_	_	_
11-3	1371-1372	a	object[91]	new[91]	coref	12-1[0_91]
11-4	1373-1387	broad-spectrum	object[91]	new[91]	_	_
11-5	1388-1397	antiviral	object[91]	new[91]	_	_
11-6	1398-1406	compound	substance|object[91]	new|new[91]	_	_
11-7	1407-1416	Ribavirin	object[91]	new[91]	_	_
11-8	1417-1419	to	_	_	_	_
11-9	1420-1424	test	_	_	_	_
11-10	1425-1428	the	abstract[92]	new[92]	_	_
11-11	1429-1439	hypothesis	abstract[92]	new[92]	_	_
11-12	1440-1444	that	_	_	_	_
11-13	1445-1446	(	abstract[93]	new[93]	_	_
11-14	1447-1448	a	abstract[93]	new[93]	_	_
11-15	1449-1450	)	abstract[93]	new[93]	_	_
11-16	1451-1461	inhibition	abstract[93]	new[93]	_	_
11-17	1462-1464	of	abstract[93]	new[93]	_	_
11-18	1465-1468	gut	abstract[93]|object[94]	new[93]|giv[94]	coref	19-14[170_94]
11-19	1469-1476	viruses	abstract[93]|object[94]	new[93]|giv[94]	_	_
11-20	1477-1479	in	abstract[93]|object[94]	new[93]|giv[94]	_	_
11-21	1480-1483	the	abstract[93]|object[94]|person[95]	new[93]|giv[94]|giv[95]	coref	20-12[0_95]
11-22	1484-1488	host	abstract[93]|object[94]|person[95]	new[93]|giv[94]|giv[95]	_	_
11-23	1489-1492	may	_	_	_	_
11-24	1493-1498	prove	_	_	_	_
11-25	1499-1502	the	abstract[96]	new[96]	_	_
11-26	1503-1507	role	abstract[96]	new[96]	_	_
11-27	1508-1510	of	abstract[96]	new[96]	_	_
11-28	1511-1514	gut	abstract[96]|abstract|abstract[98]	new[96]|giv|giv[98]	coref|coref|coref|coref	11-45[0_98]|14-20[124_0]|11-45[0_98]|14-20[124_0]
11-29	1515-1521	virome	abstract[96]|abstract[98]	new[96]|giv[98]	_	_
11-30	1522-1524	in	abstract[96]|abstract[98]	new[96]|giv[98]	_	_
11-31	1525-1528	GWI	abstract[96]|abstract[98]|event	new[96]|giv[98]|giv	coref	11-48
11-32	1529-1532	and	_	_	_	_
11-33	1533-1534	(	_	_	_	_
11-34	1535-1536	b	place	new	_	_
11-35	1537-1538	)	_	_	_	_
11-36	1539-1548	antiviral	abstract[101]	new[101]	coref	16-7[149_101]
11-37	1549-1558	treatment	abstract[101]	new[101]	_	_
11-38	1559-1562	may	_	_	_	_
11-39	1563-1567	help	_	_	_	_
11-40	1568-1570	to	_	_	_	_
11-41	1571-1582	reconstruct	_	_	_	_
11-42	1583-1586	and	_	_	_	_
11-43	1587-1594	restore	_	_	_	_
11-44	1595-1598	the	abstract[103]	new[103]	_	_
11-45	1599-1605	virome	abstract|abstract[103]	giv|new[103]	coref	15-11[129_0]
11-46	1606-1615	signature	abstract[103]	new[103]	_	_
11-47	1616-1618	in	abstract[103]	new[103]	_	_
11-48	1619-1622	GWI	abstract[103]|abstract	new[103]|giv	coref	19-30
11-49	1623-1624	.	_	_	_	_

#Text=Ribavirin has been extensively used as a therapeutic drug in several viral infections including Paramyxovirus , Adenovirus , and RSV infections .
12-1	1625-1634	Ribavirin	object	giv	coref	13-5
12-2	1635-1638	has	_	_	_	_
12-3	1639-1643	been	_	_	_	_
12-4	1644-1655	extensively	_	_	_	_
12-5	1656-1660	used	_	_	_	_
12-6	1661-1663	as	_	_	_	_
12-7	1664-1665	a	_	_	_	_
12-8	1666-1677	therapeutic	_	_	_	_
12-9	1678-1682	drug	_	_	_	_
12-10	1683-1685	in	_	_	_	_
12-11	1686-1693	several	abstract[106]	new[106]	_	_
12-12	1694-1699	viral	abstract[106]	new[106]	_	_
12-13	1700-1710	infections	abstract[106]	new[106]	_	_
12-14	1711-1720	including	abstract[106]	new[106]	_	_
12-15	1721-1734	Paramyxovirus	abstract[106]|abstract	new[106]|new	_	_
12-16	1735-1736	,	abstract[106]	new[106]	_	_
12-17	1737-1747	Adenovirus	abstract[106]|place	new[106]|new	_	_
12-18	1748-1749	,	abstract[106]	new[106]	_	_
12-19	1750-1753	and	abstract[106]	new[106]	_	_
12-20	1754-1757	RSV	abstract[106]|object|abstract[110]	new[106]|new|new[110]	_	_
12-21	1758-1768	infections	abstract[106]|abstract[110]	new[106]|new[110]	_	_
12-22	1769-1770	.	_	_	_	_

#Text=Our results showed that Ribavirin reverses GWI-induced alterations of the enteric viral community .
13-1	1771-1774	Our	person|abstract[112]	giv|new[112]	ana|coref|ana|coref	15-3|18-1[0_112]|15-3|18-1[0_112]
13-2	1775-1782	results	abstract[112]	new[112]	_	_
13-3	1783-1789	showed	_	_	_	_
13-4	1790-1794	that	_	_	_	_
13-5	1795-1804	Ribavirin	substance	giv	coref	16-7
13-6	1805-1813	reverses	_	_	_	_
13-7	1814-1825	GWI-induced	abstract[114]	new[114]	_	_
13-8	1826-1837	alterations	abstract[114]	new[114]	_	_
13-9	1838-1840	of	abstract[114]	new[114]	_	_
13-10	1841-1844	the	abstract[114]|abstract[116]	new[114]|new[116]	coref	14-17[123_116]
13-11	1845-1852	enteric	abstract[114]|person|abstract[116]	new[114]|giv|new[116]	coref	14-2
13-12	1853-1858	viral	abstract[114]|abstract[116]	new[114]|new[116]	_	_
13-13	1859-1868	community	abstract[114]|abstract[116]	new[114]|new[116]	_	_
13-14	1869-1870	.	_	_	_	_

#Text=The enteric bacteriophage-bacteria ( parasite-host ) interaction is an essential phenomenon to regulate both bacterial and viral community in the gut and play as a key role in gut health .
14-1	1871-1874	The	abstract[118]	new[118]	_	_
14-2	1875-1882	enteric	person|abstract[118]	giv|new[118]	coref	29-6
14-3	1883-1905	bacteriophage-bacteria	abstract[118]	new[118]	_	_
14-4	1906-1907	(	_	_	_	_
14-5	1908-1921	parasite-host	person	new	_	_
14-6	1922-1923	)	_	_	_	_
14-7	1924-1935	interaction	abstract	new	coref	14-9[121_0]
14-8	1936-1938	is	_	_	_	_
14-9	1939-1941	an	abstract[121]	giv[121]	_	_
14-10	1942-1951	essential	abstract[121]	giv[121]	_	_
14-11	1952-1962	phenomenon	abstract[121]	giv[121]	_	_
14-12	1963-1965	to	_	_	_	_
14-13	1966-1974	regulate	_	_	_	_
14-14	1975-1979	both	substance[122]	giv[122]	_	_
14-15	1980-1989	bacterial	substance[122]	giv[122]	_	_
14-16	1990-1993	and	_	_	_	_
14-17	1994-1999	viral	abstract[123]	giv[123]	_	_
14-18	2000-2009	community	abstract[123]	giv[123]	_	_
14-19	2010-2012	in	abstract[123]	giv[123]	_	_
14-20	2013-2016	the	abstract[123]|abstract[124]	giv[123]|giv[124]	coref	14-29[0_124]
14-21	2017-2020	gut	abstract[123]|abstract[124]	giv[123]|giv[124]	_	_
14-22	2021-2024	and	_	_	_	_
14-23	2025-2029	play	_	_	_	_
14-24	2030-2032	as	_	_	_	_
14-25	2033-2034	a	_	_	_	_
14-26	2035-2038	key	_	_	_	_
14-27	2039-2043	role	_	_	_	_
14-28	2044-2046	in	_	_	_	_
14-29	2047-2050	gut	abstract|abstract[126]	giv|new[126]	coref|coref	17-4|17-4
14-30	2051-2057	health	abstract[126]	new[126]	_	_
14-31	2058-2059	.	_	_	_	_

#Text=Here , we found an independent or cumulative effect of both virome and bacteriome dysbiosis in weakening of GI tight junctions ( increased Claudin-2 and decreased ZO1 and Occludin ) , GI inflammation ( increased MCP1 and IL6 ) , systemic inflammation ( increased serum IFNγ and IL6 ) and neuroinflammation ( increased microglia activation and brain IL6 ) .
15-1	2060-2064	Here	_	_	_	_
15-2	2065-2066	,	_	_	_	_
15-3	2067-2069	we	person	giv	ana	19-43
15-4	2070-2075	found	_	_	_	_
15-5	2076-2078	an	abstract[128]	new[128]	_	_
15-6	2079-2090	independent	abstract[128]	new[128]	_	_
15-7	2091-2093	or	abstract[128]	new[128]	_	_
15-8	2094-2104	cumulative	abstract[128]	new[128]	_	_
15-9	2105-2111	effect	abstract[128]	new[128]	_	_
15-10	2112-2114	of	abstract[128]	new[128]	_	_
15-11	2115-2119	both	abstract[128]|abstract[129]|abstract[130]	new[128]|giv[129]|new[130]	coref|coref|coref|coref	24-12[0_129]|25-55[246_130]|24-12[0_129]|25-55[246_130]
15-12	2120-2126	virome	abstract[128]|abstract[129]|abstract[130]	new[128]|giv[129]|new[130]	_	_
15-13	2127-2130	and	abstract[128]|abstract[130]	new[128]|new[130]	_	_
15-14	2131-2141	bacteriome	abstract[128]|abstract[130]|abstract[131]	new[128]|new[130]|giv[131]	coref	24-15[0_131]
15-15	2142-2151	dysbiosis	abstract[128]|abstract[130]|abstract[131]	new[128]|new[130]|giv[131]	_	_
15-16	2152-2154	in	_	_	_	_
15-17	2155-2164	weakening	abstract[132]	new[132]	_	_
15-18	2165-2167	of	abstract[132]	new[132]	_	_
15-19	2168-2170	GI	abstract[132]|place|person[134]	new[132]|giv|new[134]	appos|coref|appos|coref	15-23[136_134]|15-32|15-23[136_134]|15-32
15-20	2171-2176	tight	abstract[132]|person[134]	new[132]|new[134]	_	_
15-21	2177-2186	junctions	abstract[132]|person[134]	new[132]|new[134]	_	_
15-22	2187-2188	(	_	_	_	_
15-23	2189-2198	increased	substance[135]|place[136]	new[135]|giv[136]	_	_
15-24	2199-2208	Claudin-2	substance[135]|place[136]	new[135]|giv[136]	_	_
15-25	2209-2212	and	place[136]	giv[136]	_	_
15-26	2213-2222	decreased	place[136]	giv[136]	_	_
15-27	2223-2226	ZO1	place[136]	giv[136]	_	_
15-28	2227-2230	and	place[136]	giv[136]	_	_
15-29	2231-2239	Occludin	place[136]	giv[136]	_	_
15-30	2240-2241	)	_	_	_	_
15-31	2242-2243	,	_	_	_	_
15-32	2244-2246	GI	object|abstract[138]	giv|giv[138]	appos|coref|appos|coref	15-35[139_138]|16-10|15-35[139_138]|16-10
15-33	2247-2259	inflammation	abstract[138]	giv[138]	_	_
15-34	2260-2261	(	_	_	_	_
15-35	2262-2271	increased	abstract[139]	giv[139]	coref	15-41[140_139]
15-36	2272-2276	MCP1	abstract[139]	giv[139]	_	_
15-37	2277-2280	and	abstract[139]	giv[139]	_	_
15-38	2281-2284	IL6	abstract[139]	giv[139]	_	_
15-39	2285-2286	)	_	_	_	_
15-40	2287-2288	,	_	_	_	_
15-41	2289-2297	systemic	abstract[140]	giv[140]	coref	26-7[250_140]
15-42	2298-2310	inflammation	abstract[140]	giv[140]	_	_
15-43	2311-2312	(	abstract[140]	giv[140]	_	_
15-44	2313-2322	increased	abstract[140]	giv[140]	_	_
15-45	2323-2328	serum	abstract[140]|abstract|abstract[142]	giv[140]|new|new[142]	coref|coref	27-23|27-23
15-46	2329-2333	IFNγ	abstract[140]|abstract[142]	giv[140]|new[142]	_	_
15-47	2334-2337	and	abstract[140]	giv[140]	_	_
15-48	2338-2341	IL6	abstract[140]	giv[140]	_	_
15-49	2342-2343	)	abstract[140]	giv[140]	_	_
15-50	2344-2347	and	_	_	_	_
15-51	2348-2365	neuroinflammation	abstract	giv	appos	15-53[145_0]
15-52	2366-2367	(	_	_	_	_
15-53	2368-2377	increased	abstract[145]	giv[145]	coref	16-1[147_145]
15-54	2378-2387	microglia	place|abstract[145]	new|giv[145]	_	_
15-55	2388-2398	activation	abstract[145]	giv[145]	_	_
15-56	2399-2402	and	abstract[145]	giv[145]	_	_
15-57	2403-2408	brain	abstract[145]|object	giv[145]|new	_	_
15-58	2409-2412	IL6	abstract[145]	giv[145]	_	_
15-59	2413-2414	)	_	_	_	_
15-60	2415-2416	.	_	_	_	_

#Text=The present study also showed that Ribavirin treatment improved GI tight junction assembly and subsequently decreasing GI and neuroinflammation .
16-1	2417-2420	The	abstract[147]	giv[147]	coref	16-19[0_147]
16-2	2421-2428	present	abstract[147]	giv[147]	_	_
16-3	2429-2434	study	abstract[147]	giv[147]	_	_
16-4	2435-2439	also	_	_	_	_
16-5	2440-2446	showed	_	_	_	_
16-6	2447-2451	that	_	_	_	_
16-7	2452-2461	Ribavirin	substance|abstract[149]	giv|giv[149]	coref|coref	18-13|18-13
16-8	2462-2471	treatment	abstract[149]	giv[149]	_	_
16-9	2472-2480	improved	_	_	_	_
16-10	2481-2483	GI	abstract|organization[152]	giv|new[152]	coref|coref	16-17|16-17
16-11	2484-2489	tight	organization[152]	new[152]	_	_
16-12	2490-2498	junction	place|organization[152]	new|new[152]	_	_
16-13	2499-2507	assembly	organization[152]	new[152]	_	_
16-14	2508-2511	and	_	_	_	_
16-15	2512-2524	subsequently	_	_	_	_
16-16	2525-2535	decreasing	_	_	_	_
16-17	2536-2538	GI	abstract	giv	coref	17-11[158_0]
16-18	2539-2542	and	_	_	_	_
16-19	2543-2560	neuroinflammation	abstract	giv	coref	24-2[208_0]
16-20	2561-2562	.	_	_	_	_

#Text=Interestingly , inducing gut sterility by using antibiotics also improves such GI and neurological complications .
17-1	2563-2576	Interestingly	_	_	_	_
17-2	2577-2578	,	_	_	_	_
17-3	2579-2587	inducing	_	_	_	_
17-4	2588-2591	gut	abstract|abstract[156]	giv|new[156]	coref|coref	25-55|25-55
17-5	2592-2601	sterility	abstract[156]	new[156]	_	_
17-6	2602-2604	by	_	_	_	_
17-7	2605-2610	using	_	_	_	_
17-8	2611-2622	antibiotics	substance	new	coref	18-15
17-9	2623-2627	also	_	_	_	_
17-10	2628-2636	improves	_	_	_	_
17-11	2637-2641	such	abstract[158]|abstract[159]	giv[158]|giv[159]	coref|coref|coref|coref	18-22[0_158]|18-21[165_159]|18-22[0_158]|18-21[165_159]
17-12	2642-2644	GI	abstract[158]|abstract[159]	giv[158]|giv[159]	_	_
17-13	2645-2648	and	abstract[159]	giv[159]	_	_
17-14	2649-2661	neurological	abstract[159]	giv[159]	_	_
17-15	2662-2675	complications	abstract[159]	giv[159]	_	_
17-16	2676-2677	.	_	_	_	_

#Text=Results reported here are also strongly supported by previous such studies where Ribavirin or antibiotics were applied as therapeutics in other GI complications and neurological illnesses .
18-1	2678-2685	Results	abstract	giv	coref	27-1[256_0]
18-2	2686-2694	reported	_	_	_	_
18-3	2695-2699	here	_	_	_	_
18-4	2700-2703	are	_	_	_	_
18-5	2704-2708	also	_	_	_	_
18-6	2709-2717	strongly	_	_	_	_
18-7	2718-2727	supported	_	_	_	_
18-8	2728-2730	by	_	_	_	_
18-9	2731-2739	previous	abstract[161]	new[161]	_	_
18-10	2740-2744	such	abstract[161]	new[161]	_	_
18-11	2745-2752	studies	abstract[161]	new[161]	_	_
18-12	2753-2758	where	_	_	_	_
18-13	2759-2768	Ribavirin	substance	giv	coref	26-12
18-14	2769-2771	or	_	_	_	_
18-15	2772-2783	antibiotics	substance	giv	coref	26-14
18-16	2784-2788	were	_	_	_	_
18-17	2789-2796	applied	_	_	_	_
18-18	2797-2799	as	_	_	_	_
18-19	2800-2812	therapeutics	_	_	_	_
18-20	2813-2815	in	_	_	_	_
18-21	2816-2821	other	abstract[165]	giv[165]	_	_
18-22	2822-2824	GI	abstract|abstract[165]	giv|giv[165]	_	_
18-23	2825-2838	complications	abstract[165]	giv[165]	_	_
18-24	2839-2842	and	abstract[165]	giv[165]	_	_
18-25	2843-2855	neurological	abstract[165]|abstract[166]	giv[165]|new[166]	_	_
18-26	2856-2865	illnesses	abstract[165]|abstract[166]	giv[165]|new[166]	_	_
18-27	2866-2867	.	_	_	_	_

#Text=However , nonavailability of germ-free and gnotobiotic mice or mice completely devoid of gut viruses prove to be a serious handicap in establishing the exact role of viruses in GWI or any other disease pathology though use of antiviral cocktails similar to our approach have been shown to serve the purpose .
19-1	2868-2875	However	_	_	_	_
19-2	2876-2877	,	_	_	_	_
19-3	2878-2893	nonavailability	_	_	_	_
19-4	2894-2896	of	_	_	_	_
19-5	2897-2906	germ-free	object	new	_	_
19-6	2907-2910	and	_	_	_	_
19-7	2911-2922	gnotobiotic	animal[168]	new[168]	_	_
19-8	2923-2927	mice	animal[168]	new[168]	_	_
19-9	2928-2930	or	_	_	_	_
19-10	2931-2935	mice	animal[169]	new[169]	_	_
19-11	2936-2946	completely	animal[169]	new[169]	_	_
19-12	2947-2953	devoid	animal[169]	new[169]	_	_
19-13	2954-2956	of	_	_	_	_
19-14	2957-2960	gut	object[170]	giv[170]	coref	19-28[173_170]
19-15	2961-2968	viruses	object[170]	giv[170]	_	_
19-16	2969-2974	prove	_	_	_	_
19-17	2975-2977	to	_	_	_	_
19-18	2978-2980	be	_	_	_	_
19-19	2981-2982	a	abstract[171]	new[171]	_	_
19-20	2983-2990	serious	abstract[171]	new[171]	_	_
19-21	2991-2999	handicap	abstract[171]	new[171]	_	_
19-22	3000-3002	in	_	_	_	_
19-23	3003-3015	establishing	_	_	_	_
19-24	3016-3019	the	abstract[172]	new[172]	coref	31-27[292_172]
19-25	3020-3025	exact	abstract[172]	new[172]	_	_
19-26	3026-3030	role	abstract[172]	new[172]	_	_
19-27	3031-3033	of	abstract[172]	new[172]	_	_
19-28	3034-3041	viruses	abstract[172]|object[173]	new[172]|giv[173]	coref	29-5[272_173]
19-29	3042-3044	in	abstract[172]|object[173]	new[172]|giv[173]	_	_
19-30	3045-3048	GWI	abstract[172]|object[173]|event	new[172]|giv[173]|giv	coref	28-13
19-31	3049-3051	or	abstract[172]|object[173]	new[172]|giv[173]	_	_
19-32	3052-3055	any	abstract[172]|object[173]|abstract[176]	new[172]|giv[173]|giv[176]	coref	20-12[188_176]
19-33	3056-3061	other	abstract[172]|object[173]|abstract[176]	new[172]|giv[173]|giv[176]	_	_
19-34	3062-3069	disease	abstract[172]|object[173]|abstract|abstract[176]	new[172]|giv[173]|giv|giv[176]	_	_
19-35	3070-3079	pathology	abstract[172]|object[173]|abstract[176]	new[172]|giv[173]|giv[176]	_	_
19-36	3080-3086	though	_	_	_	_
19-37	3087-3090	use	abstract[177]	new[177]	_	_
19-38	3091-3093	of	abstract[177]	new[177]	_	_
19-39	3094-3103	antiviral	abstract[177]|object[178]	new[177]|new[178]	_	_
19-40	3104-3113	cocktails	abstract[177]|object[178]	new[177]|new[178]	_	_
19-41	3114-3121	similar	abstract[177]	new[177]	_	_
19-42	3122-3124	to	_	_	_	_
19-43	3125-3128	our	person|abstract[180]	giv|new[180]	ana|ana	24-5|24-5
19-44	3129-3137	approach	abstract[180]	new[180]	_	_
19-45	3138-3142	have	_	_	_	_
19-46	3143-3147	been	_	_	_	_
19-47	3148-3153	shown	_	_	_	_
19-48	3154-3156	to	_	_	_	_
19-49	3157-3162	serve	_	_	_	_
19-50	3163-3166	the	abstract[181]	new[181]	_	_
19-51	3167-3174	purpose	abstract[181]	new[181]	_	_
19-52	3175-3176	.	_	_	_	_

#Text=Gut microbiome is a collection of trillions of microorganisms that modulated host pathology and physiology through different mechanisms .
20-1	3177-3180	Gut	person|abstract[183]	giv|new[183]	coref|coref	20-4[184_183]|20-4[184_183]
20-2	3181-3191	microbiome	abstract[183]	new[183]	_	_
20-3	3192-3194	is	_	_	_	_
20-4	3195-3196	a	abstract[184]	giv[184]	coref	22-6[0_184]
20-5	3197-3207	collection	abstract[184]	giv[184]	_	_
20-6	3208-3210	of	abstract[184]	giv[184]	_	_
20-7	3211-3220	trillions	abstract[184]|person[185]	giv[184]|new[185]	_	_
20-8	3221-3223	of	abstract[184]|person[185]	giv[184]|new[185]	_	_
20-9	3224-3238	microorganisms	abstract[184]|person[185]|abstract	giv[184]|new[185]|new	_	_
20-10	3239-3243	that	_	_	_	_
20-11	3244-3253	modulated	_	_	_	_
20-12	3254-3258	host	person|abstract[188]	giv|giv[188]	coref|coref	31-36[295_0]|31-36[295_0]
20-13	3259-3268	pathology	abstract[188]	giv[188]	_	_
20-14	3269-3272	and	_	_	_	_
20-15	3273-3283	physiology	abstract	new	_	_
20-16	3284-3291	through	_	_	_	_
20-17	3292-3301	different	abstract[190]	new[190]	coref	31-33[294_190]
20-18	3302-3312	mechanisms	abstract[190]	new[190]	_	_
20-19	3313-3314	.	_	_	_	_

#Text=Previous reports have suggested that the intestinal microbiota had a strong influence on the mucosal immune system and vice versa .
21-1	3315-3323	Previous	abstract[191]	new[191]	_	_
21-2	3324-3331	reports	abstract[191]	new[191]	_	_
21-3	3332-3336	have	_	_	_	_
21-4	3337-3346	suggested	_	_	_	_
21-5	3347-3351	that	_	_	_	_
21-6	3352-3355	the	object[193]	new[193]	_	_
21-7	3356-3366	intestinal	person|object[193]	new|new[193]	_	_
21-8	3367-3377	microbiota	object[193]	new[193]	_	_
21-9	3378-3381	had	_	_	_	_
21-10	3382-3383	a	abstract[194]	new[194]	_	_
21-11	3384-3390	strong	abstract[194]	new[194]	_	_
21-12	3391-3400	influence	abstract[194]	new[194]	_	_
21-13	3401-3403	on	abstract[194]	new[194]	_	_
21-14	3404-3407	the	abstract[194]|abstract[196]	new[194]|new[196]	_	_
21-15	3408-3415	mucosal	abstract[194]|abstract[196]	new[194]|new[196]	_	_
21-16	3416-3422	immune	abstract[194]|abstract|abstract[196]	new[194]|new|new[196]	coref	22-11
21-17	3423-3429	system	abstract[194]|abstract[196]	new[194]|new[196]	_	_
21-18	3430-3433	and	abstract[194]	new[194]	_	_
21-19	3434-3438	vice	abstract[194]|person[197]	new[194]|new[197]	_	_
21-20	3439-3444	versa	abstract[194]|person[197]	new[194]|new[197]	_	_
21-21	3445-3446	.	_	_	_	_

#Text=A balanced pathogen and commensal microbiome composition maintain the microbiome-host immune homeostasis .
22-1	3447-3448	A	abstract[198]	new[198]	_	_
22-2	3449-3457	balanced	abstract[198]	new[198]	_	_
22-3	3458-3466	pathogen	abstract[198]	new[198]	_	_
22-4	3467-3470	and	_	_	_	_
22-5	3471-3480	commensal	abstract[200]	new[200]	_	_
22-6	3481-3491	microbiome	abstract|abstract[200]	giv|new[200]	coref	23-6[204_0]
22-7	3492-3503	composition	abstract[200]	new[200]	_	_
22-8	3504-3512	maintain	_	_	_	_
22-9	3513-3516	the	abstract[202]	new[202]	_	_
22-10	3517-3532	microbiome-host	abstract[202]	new[202]	_	_
22-11	3533-3539	immune	abstract|abstract[202]	giv|new[202]	coref	23-13
22-12	3540-3551	homeostasis	abstract[202]	new[202]	_	_
22-13	3552-3553	.	_	_	_	_

#Text=However , any alteration in the microbiome may activate innate and adaptive immune responses and may progress to an inflammatory phenotype .
23-1	3554-3561	However	_	_	_	_
23-2	3562-3563	,	_	_	_	_
23-3	3564-3567	any	abstract[203]	new[203]	_	_
23-4	3568-3578	alteration	abstract[203]	new[203]	_	_
23-5	3579-3581	in	abstract[203]	new[203]	_	_
23-6	3582-3585	the	abstract[203]|abstract[204]	new[203]|giv[204]	coref	25-58[0_204]
23-7	3586-3596	microbiome	abstract[203]|abstract[204]	new[203]|giv[204]	_	_
23-8	3597-3600	may	_	_	_	_
23-9	3601-3609	activate	_	_	_	_
23-10	3610-3616	innate	abstract[206]	new[206]	_	_
23-11	3617-3620	and	abstract[206]	new[206]	_	_
23-12	3621-3629	adaptive	abstract[206]	new[206]	_	_
23-13	3630-3636	immune	abstract|abstract[206]	giv|new[206]	_	_
23-14	3637-3646	responses	abstract[206]	new[206]	_	_
23-15	3647-3650	and	_	_	_	_
23-16	3651-3654	may	_	_	_	_
23-17	3655-3663	progress	_	_	_	_
23-18	3664-3666	to	_	_	_	_
23-19	3667-3669	an	abstract[207]	new[207]	_	_
23-20	3670-3682	inflammatory	abstract[207]	new[207]	_	_
23-21	3683-3692	phenotype	abstract[207]	new[207]	_	_
23-22	3693-3694	.	_	_	_	_

#Text=In the present study we have shown that the GW chemical-induced virome richness and dysbiosis showed a strong association with activated Toll-like receptor-7 ( TLR7 ) and TLR9 mediated proinflammatory pathways .
24-1	3695-3697	In	_	_	_	_
24-2	3698-3701	the	abstract[208]	giv[208]	coref	25-8[223_208]
24-3	3702-3709	present	abstract[208]	giv[208]	_	_
24-4	3710-3715	study	abstract[208]	giv[208]	_	_
24-5	3716-3718	we	person	giv	ana	25-1
24-6	3719-3723	have	_	_	_	_
24-7	3724-3729	shown	_	_	_	_
24-8	3730-3734	that	_	_	_	_
24-9	3735-3738	the	abstract[212]|abstract[213]	giv[212]|giv[213]	_	_
24-10	3739-3741	GW	abstract|abstract[212]|abstract[213]	giv|giv[212]|giv[213]	_	_
24-11	3742-3758	chemical-induced	abstract[212]|abstract[213]	giv[212]|giv[213]	_	_
24-12	3759-3765	virome	abstract|abstract[212]|abstract[213]	giv|giv[212]|giv[213]	coref	25-55[245_0]
24-13	3766-3774	richness	abstract[212]|abstract[213]	giv[212]|giv[213]	_	_
24-14	3775-3778	and	abstract[213]	giv[213]	_	_
24-15	3779-3788	dysbiosis	abstract[213]|abstract	giv[213]|giv	coref	25-58[248_0]
24-16	3789-3795	showed	_	_	_	_
24-17	3796-3797	a	abstract[215]	new[215]	_	_
24-18	3798-3804	strong	abstract[215]	new[215]	_	_
24-19	3805-3816	association	abstract[215]	new[215]	_	_
24-20	3817-3821	with	abstract[215]	new[215]	_	_
24-21	3822-3831	activated	abstract[215]|abstract[217]	new[215]|new[217]	appos	24-25[0_217]
24-22	3832-3841	Toll-like	abstract[215]|abstract|abstract[217]	new[215]|new|new[217]	_	_
24-23	3842-3852	receptor-7	abstract[215]|abstract[217]	new[215]|new[217]	_	_
24-24	3853-3854	(	_	_	_	_
24-25	3855-3859	TLR7	abstract	giv	coref	25-18
24-26	3860-3861	)	_	_	_	_
24-27	3862-3865	and	_	_	_	_
24-28	3866-3870	TLR9	abstract	new	_	_
24-29	3871-3879	mediated	_	_	_	_
24-30	3880-3895	proinflammatory	abstract[220]	new[220]	coref	26-17[254_220]
24-31	3896-3904	pathways	abstract[220]	new[220]	_	_
24-32	3905-3906	.	_	_	_	_

#Text=We also found that the expression and activation of downstream signaling molecules including TLR7-MyD88 ( binding of TLR7 with adaptor molecule myosin D88 ) , TLR9-MyD88 , or TLR4-Flottilin ( localization of TLR4 in lipid raft ) complex formation , TRAF6 , IKK-α , and p65 ( NFκB activation ) have been increased upon gut virome and microbiome dysbiosis .
25-1	3907-3909	We	person	giv	ana	27-5
25-2	3910-3914	also	_	_	_	_
25-3	3915-3920	found	_	_	_	_
25-4	3921-3925	that	_	_	_	_
25-5	3926-3929	the	abstract[222]	new[222]	_	_
25-6	3930-3940	expression	abstract[222]	new[222]	_	_
25-7	3941-3944	and	_	_	_	_
25-8	3945-3955	activation	abstract[223]	giv[223]	coref	27-22[263_223]
25-9	3956-3958	of	abstract[223]	giv[223]	_	_
25-10	3959-3969	downstream	abstract[223]	giv[223]	_	_
25-11	3970-3979	signaling	_	_	_	_
25-12	3980-3989	molecules	object[224]	new[224]	_	_
25-13	3990-3999	including	object[224]	new[224]	_	_
25-14	4000-4010	TLR7-MyD88	object[224]|abstract	new[224]|new	_	_
25-15	4011-4012	(	object[224]	new[224]	_	_
25-16	4013-4020	binding	object[224]|object[226]	new[224]|new[226]	_	_
25-17	4021-4023	of	object[224]|object[226]	new[224]|new[226]	_	_
25-18	4024-4028	TLR7	object[224]|object[226]|abstract	new[224]|new[226]|giv	_	_
25-19	4029-4033	with	object[224]|object[226]	new[224]|new[226]	_	_
25-20	4034-4041	adaptor	object[224]|object[226]|substance|abstract[229]	new[224]|new[226]|new|new[229]	appos|appos	25-22[231_229]|25-22[231_229]
25-21	4042-4050	molecule	object[224]|object[226]|abstract[229]	new[224]|new[226]|new[229]	_	_
25-22	4051-4057	myosin	object[224]|person|abstract[231]	new[224]|new|giv[231]	_	_
25-23	4058-4061	D88	object[224]|abstract[231]	new[224]|giv[231]	_	_
25-24	4062-4063	)	object[224]	new[224]	_	_
25-25	4064-4065	,	object[224]	new[224]	_	_
25-26	4066-4076	TLR9-MyD88	object[224]|abstract	new[224]|new	_	_
25-27	4077-4078	,	object[224]	new[224]	_	_
25-28	4079-4081	or	object[224]	new[224]	_	_
25-29	4082-4096	TLR4-Flottilin	object[224]|abstract	new[224]|new	_	_
25-30	4097-4098	(	_	_	_	_
25-31	4099-4111	localization	abstract[234]	new[234]	_	_
25-32	4112-4114	of	abstract[234]	new[234]	_	_
25-33	4115-4119	TLR4	abstract[234]|abstract	new[234]|new	_	_
25-34	4120-4122	in	abstract[234]	new[234]	_	_
25-35	4123-4128	lipid	abstract[234]|abstract|object[237]	new[234]|new|new[237]	_	_
25-36	4129-4133	raft	abstract[234]|object[237]	new[234]|new[237]	_	_
25-37	4134-4135	)	_	_	_	_
25-38	4136-4143	complex	abstract[238]	new[238]	_	_
25-39	4144-4153	formation	abstract[238]	new[238]	_	_
25-40	4154-4155	,	_	_	_	_
25-41	4156-4161	TRAF6	abstract	new	_	_
25-42	4162-4163	,	_	_	_	_
25-43	4164-4169	IKK-α	object	new	_	_
25-44	4170-4171	,	_	_	_	_
25-45	4172-4175	and	_	_	_	_
25-46	4176-4179	p65	abstract	new	appos	25-48[243_0]
25-47	4180-4181	(	_	_	_	_
25-48	4182-4186	NFκB	abstract|abstract[243]	new|giv[243]	coref|coref	30-10[281_243]|30-10[281_243]
25-49	4187-4197	activation	abstract[243]	giv[243]	_	_
25-50	4198-4199	)	_	_	_	_
25-51	4200-4204	have	_	_	_	_
25-52	4205-4209	been	_	_	_	_
25-53	4210-4219	increased	_	_	_	_
25-54	4220-4224	upon	_	_	_	_
25-55	4225-4228	gut	abstract|abstract[245]|abstract[246]	giv|giv[245]|giv[246]	_	_
25-56	4229-4235	virome	abstract[245]|abstract[246]	giv[245]|giv[246]	_	_
25-57	4236-4239	and	abstract[246]	giv[246]	_	_
25-58	4240-4250	microbiome	abstract[246]|abstract|abstract[248]	giv[246]|giv|giv[248]	coref|coref	26-1[249_248]|26-1[249_248]
25-59	4251-4260	dysbiosis	abstract[246]|abstract[248]	giv[246]|giv[248]	_	_
25-60	4261-4262	.	_	_	_	_

#Text=The dysbiosis was also accompanied by increased inflammation while use of Ribavirin or antibiotics independently downregulated these pathways and subsequently inflammation .
26-1	4263-4266	The	abstract[249]	giv[249]	_	_
26-2	4267-4276	dysbiosis	abstract[249]	giv[249]	_	_
26-3	4277-4280	was	_	_	_	_
26-4	4281-4285	also	_	_	_	_
26-5	4286-4297	accompanied	_	_	_	_
26-6	4298-4300	by	_	_	_	_
26-7	4301-4310	increased	abstract[250]	giv[250]	coref	26-20[255_250]
26-8	4311-4323	inflammation	abstract[250]	giv[250]	_	_
26-9	4324-4329	while	_	_	_	_
26-10	4330-4333	use	abstract[251]	new[251]	_	_
26-11	4334-4336	of	abstract[251]	new[251]	_	_
26-12	4337-4346	Ribavirin	abstract[251]|substance	new[251]|giv	_	_
26-13	4347-4349	or	abstract[251]	new[251]	_	_
26-14	4350-4361	antibiotics	abstract[251]|substance	new[251]|giv	_	_
26-15	4362-4375	independently	_	_	_	_
26-16	4376-4389	downregulated	_	_	_	_
26-17	4390-4395	these	abstract[254]	giv[254]	_	_
26-18	4396-4404	pathways	abstract[254]	giv[254]	_	_
26-19	4405-4408	and	abstract[254]	giv[254]	_	_
26-20	4409-4421	subsequently	abstract[254]|abstract[255]	giv[254]|giv[255]	coref	27-22[262_255]
26-21	4422-4434	inflammation	abstract[254]|abstract[255]	giv[254]|giv[255]	_	_
26-22	4435-4436	.	_	_	_	_

#Text=The above results prompted us to study whether virome diversity had a direct connection to a sustained systemic inflammatory response via increased serum IL6 or vice versa .
27-1	4437-4440	The	abstract[256]	giv[256]	_	_
27-2	4441-4446	above	abstract[256]	giv[256]	_	_
27-3	4447-4454	results	abstract[256]	giv[256]	_	_
27-4	4455-4463	prompted	_	_	_	_
27-5	4464-4466	us	person	giv	ana	28-1
27-6	4467-4469	to	_	_	_	_
27-7	4470-4475	study	_	_	_	_
27-8	4476-4483	whether	_	_	_	_
27-9	4484-4490	virome	abstract[258]	new[258]	coref	28-6[267_258]
27-10	4491-4500	diversity	abstract[258]	new[258]	_	_
27-11	4501-4504	had	_	_	_	_
27-12	4505-4506	a	abstract[259]	new[259]	_	_
27-13	4507-4513	direct	abstract[259]	new[259]	_	_
27-14	4514-4524	connection	abstract[259]	new[259]	_	_
27-15	4525-4527	to	abstract[259]	new[259]	_	_
27-16	4528-4529	a	abstract[259]|abstract[260]	new[259]|new[260]	coref	29-15[275_260]
27-17	4530-4539	sustained	abstract[259]|abstract[260]	new[259]|new[260]	_	_
27-18	4540-4548	systemic	abstract[259]|abstract[260]	new[259]|new[260]	_	_
27-19	4549-4561	inflammatory	abstract[259]|abstract[260]	new[259]|new[260]	_	_
27-20	4562-4570	response	abstract[259]|abstract[260]	new[259]|new[260]	_	_
27-21	4571-4574	via	abstract[259]|abstract[260]	new[259]|new[260]	_	_
27-22	4575-4584	increased	abstract[259]|abstract[260]|abstract[262]|abstract[263]	new[259]|new[260]|giv[262]|giv[263]	coref|coref|coref|coref	28-4[0_262]|28-4[266_263]|28-4[0_262]|28-4[266_263]
27-23	4585-4590	serum	abstract[259]|abstract[260]|abstract|abstract[262]|abstract[263]	new[259]|new[260]|giv|giv[262]|giv[263]	_	_
27-24	4591-4594	IL6	abstract[259]|abstract[260]|abstract[262]|abstract[263]	new[259]|new[260]|giv[262]|giv[263]	_	_
27-25	4595-4597	or	abstract[259]|abstract[260]|abstract[263]	new[259]|new[260]|giv[263]	_	_
27-26	4598-4602	vice	abstract[259]|abstract[260]|abstract[263]	new[259]|new[260]|giv[263]	_	_
27-27	4603-4608	versa	abstract[259]|abstract[260]|abstract[263]	new[259]|new[260]|giv[263]	_	_
27-28	4609-4610	.	_	_	_	_

#Text=We found that IL6 and virome diversity had a positive correlation in GWI .
28-1	4611-4613	We	person	giv	ana	31-2
28-2	4614-4619	found	_	_	_	_
28-3	4620-4624	that	_	_	_	_
28-4	4625-4628	IL6	abstract|abstract[266]	giv|giv[266]	coref|coref|coref|coref	31-2[285_266]|31-16|31-2[285_266]|31-16
28-5	4629-4632	and	abstract[266]	giv[266]	_	_
28-6	4633-4639	virome	abstract[266]|abstract[267]	giv[266]|giv[267]	_	_
28-7	4640-4649	diversity	abstract[266]|abstract[267]	giv[266]|giv[267]	_	_
28-8	4650-4653	had	_	_	_	_
28-9	4654-4655	a	abstract[268]	new[268]	_	_
28-10	4656-4664	positive	abstract[268]	new[268]	_	_
28-11	4665-4676	correlation	abstract[268]	new[268]	_	_
28-12	4677-4679	in	abstract[268]	new[268]	_	_
28-13	4680-4683	GWI	abstract[268]|event	new[268]|giv	coref	31-31
28-14	4684-4685	.	_	_	_	_

#Text=Studies have shown that the enteric viruses can activate TLR3 signaling pathway to induce anti-inflammatory response via IFNβ production .
29-1	4686-4693	Studies	event	new	_	_
29-2	4694-4698	have	_	_	_	_
29-3	4699-4704	shown	_	_	_	_
29-4	4705-4709	that	_	_	_	_
29-5	4710-4713	the	object[272]	giv[272]	_	_
29-6	4714-4721	enteric	object|object[272]	giv|giv[272]	_	_
29-7	4722-4729	viruses	object[272]	giv[272]	_	_
29-8	4730-4733	can	_	_	_	_
29-9	4734-4742	activate	_	_	_	_
29-10	4743-4747	TLR3	abstract|abstract[274]	new|new[274]	coref|ana|coref|ana	30-11|31-27[0_274]|30-11|31-27[0_274]
29-11	4748-4757	signaling	abstract[274]	new[274]	_	_
29-12	4758-4765	pathway	abstract[274]	new[274]	_	_
29-13	4766-4768	to	_	_	_	_
29-14	4769-4775	induce	_	_	_	_
29-15	4776-4793	anti-inflammatory	abstract[275]	giv[275]	coref	30-15[282_275]
29-16	4794-4802	response	abstract[275]	giv[275]	_	_
29-17	4803-4806	via	abstract[275]	giv[275]	_	_
29-18	4807-4811	IFNβ	abstract[275]|object|abstract[277]	giv[275]|new|new[277]	ana|coref|ana|coref	30-3[0_277]|31-21[290_0]|30-3[0_277]|31-21[290_0]
29-19	4812-4822	production	abstract[275]|abstract[277]	giv[275]|new[277]	_	_
29-20	4823-4824	.	_	_	_	_

#Text=However , it has always been a conflict whether viral-induced TLR3 activation leads to pro- or anti-inflammatory response in viral pathogenesis .
30-1	4825-4832	However	_	_	_	_
30-2	4833-4834	,	_	_	_	_
30-3	4835-4837	it	event	giv	coref	30-7[279_0]
30-4	4838-4841	has	_	_	_	_
30-5	4842-4848	always	_	_	_	_
30-6	4849-4853	been	_	_	_	_
30-7	4854-4855	a	event[279]	giv[279]	_	_
30-8	4856-4864	conflict	event[279]	giv[279]	_	_
30-9	4865-4872	whether	_	_	_	_
30-10	4873-4886	viral-induced	abstract[281]	giv[281]	_	_
30-11	4887-4891	TLR3	abstract|abstract[281]	giv|giv[281]	coref	31-9
30-12	4892-4902	activation	abstract[281]	giv[281]	_	_
30-13	4903-4908	leads	_	_	_	_
30-14	4909-4911	to	_	_	_	_
30-15	4912-4916	pro-	abstract[282]	giv[282]	coref	31-13[288_282]
30-16	4917-4919	or	abstract[282]	giv[282]	_	_
30-17	4920-4937	anti-inflammatory	abstract[282]	giv[282]	_	_
30-18	4938-4946	response	abstract[282]	giv[282]	_	_
30-19	4947-4949	in	abstract[282]	giv[282]	_	_
30-20	4950-4955	viral	abstract[282]|abstract[283]	giv[282]|new[283]	_	_
30-21	4956-4968	pathogenesis	abstract[282]|abstract[283]	giv[282]|new[283]	_	_
30-22	4969-4970	.	_	_	_	_

#Text=In our study , we observed that increased TLR3 might switch to pro-inflammatory response via IL6 or fail to produce significant IFNβ in order to support its anti-inflammatory role in GWI though such mechanisms in the host remain inconclusive at this time .
31-1	4971-4973	In	_	_	_	_
31-2	4974-4977	our	person|abstract[285]	giv|giv[285]	ana|ana	31-5|31-5
31-3	4978-4983	study	abstract[285]	giv[285]	_	_
31-4	4984-4985	,	_	_	_	_
31-5	4986-4988	we	person	giv	_	_
31-6	4989-4997	observed	_	_	_	_
31-7	4998-5002	that	_	_	_	_
31-8	5003-5012	increased	_	_	_	_
31-9	5013-5017	TLR3	abstract	giv	_	_
31-10	5018-5023	might	_	_	_	_
31-11	5024-5030	switch	_	_	_	_
31-12	5031-5033	to	_	_	_	_
31-13	5034-5050	pro-inflammatory	abstract[288]	giv[288]	_	_
31-14	5051-5059	response	abstract[288]	giv[288]	_	_
31-15	5060-5063	via	abstract[288]	giv[288]	_	_
31-16	5064-5067	IL6	abstract[288]|abstract	giv[288]|giv	_	_
31-17	5068-5070	or	_	_	_	_
31-18	5071-5075	fail	_	_	_	_
31-19	5076-5078	to	_	_	_	_
31-20	5079-5086	produce	_	_	_	_
31-21	5087-5098	significant	object[290]	giv[290]	_	_
31-22	5099-5103	IFNβ	object[290]	giv[290]	_	_
31-23	5104-5106	in	_	_	_	_
31-24	5107-5112	order	_	_	_	_
31-25	5113-5115	to	_	_	_	_
31-26	5116-5123	support	_	_	_	_
31-27	5124-5127	its	abstract|abstract[292]	giv|giv[292]	_	_
31-28	5128-5145	anti-inflammatory	abstract[292]	giv[292]	_	_
31-29	5146-5150	role	abstract[292]	giv[292]	_	_
31-30	5151-5153	in	abstract[292]	giv[292]	_	_
31-31	5154-5157	GWI	abstract[292]|event	giv[292]|giv	_	_
31-32	5158-5164	though	_	_	_	_
31-33	5165-5169	such	abstract[294]	giv[294]	_	_
31-34	5170-5180	mechanisms	abstract[294]	giv[294]	_	_
31-35	5181-5183	in	abstract[294]	giv[294]	_	_
31-36	5184-5187	the	abstract[294]|place[295]	giv[294]|giv[295]	_	_
31-37	5188-5192	host	abstract[294]|place[295]	giv[294]|giv[295]	_	_
31-38	5193-5199	remain	_	_	_	_
31-39	5200-5212	inconclusive	_	_	_	_
31-40	5213-5215	at	_	_	_	_
31-41	5216-5220	this	_	_	_	_
31-42	5221-5225	time	_	_	_	_
31-43	5226-5227	.	_	_	_	_
